Quick answers
- What is Cilostazol used for?
- The FDA-approved label (Cilostazol, Apotex Corp., September 10, 2026) says: “Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. Cilostazol is a phosphodiesterase III inhibitor (PDE III inhibitor) indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Cilostazol have a boxed warning?
- Yes. The FDA label for Cilostazol has a boxed warning (“WARNING: CONTRAINDICATED IN HEART FAILURE PATIENTS”), the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Cilostazol?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Cilostazol been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Cilostazol?
- 10 companies list prescription products of Cilostazol in the FDA NDC Directory, including Aphena Pharma Solutions - Tennessee, LLC, Aurobindo Pharma Limited and Teva Pharmaceuticals USA, Inc..
What Cilostazol is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. Cilostazol is a phosphodiesterase III inhibitor (PDE III inhibitor) indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance
— FDA label: Cilostazol, Apotex Corp., effective September 10, 2026. Read the full label on DailyMed →
The FDA has 11 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Its heading: WARNING: CONTRAINDICATED IN HEART FAILURE PATIENTS
. Read it on the full label →
11 of 11 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet |
|---|---|
| Route | Oral |
| Prescription products | 18 in the FDA NDC Directory |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| cilostazol 100 mg tablet | Generic | $0.1250 per tablet |
| cilostazol 50 mg tablet | Generic | $0.1219 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Aphena Pharma Solutions - Tennessee, LLC2 products
- Aurobindo Pharma Limited2 products
- Teva Pharmaceuticals USA, Inc.2 products
- AvPAK2 products
- Apotex Corp.2 products
- Slate Run Pharmaceuticals, LLC2 products
- Bryant Ranch Prepack2 products
- Chartwell RX, LLC2 products
- AvKARE1 product
- Direct_Rx1 product
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (6)
- ANDA077019Aurobindo Pharma USA · November 23, 2004
- ANDA077021Chartwell Rx · November 23, 2004
- ANDA077027Teva · November 24, 2004
- ANDA077030Apotex · December 10, 2004
- ANDA077310Chartwell Rx · November 8, 2005
- ANDA077208Slate Run Pharma · March 29, 2006
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 242461, 242462 |
|---|---|
| SPL set ID of the quoted label | ceac1ae3-c343-28ca-c083-b748d21a15e6 |
| FDA labels (SPL) | 11 |
| FDA applications | 6 ANDA |
| Active ingredients (FDA) | CILOSTAZOL |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Cilostazol, Apotex Corp., effective September 10, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →